https://scholars.lib.ntu.edu.tw/handle/123456789/637042
標題: | Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study | 作者: | Calzavara-Pinton, Piergiacomo Čelakovská, Jarmila Lapeere, Hilde Holzer, Gregor Al-Ahmad, Mona CHIA-YU CHU Ferrucci, Silvia M. Kataoka, Yoko Rossi, Mariateresa Fomina, Daria S. Chung, Wen Hung Tzellos, Thrasyvoulos Fougerousse, Anne Claire Wu, Jiangming Ardeleanu, Marius Ozturk, Zafer E. |
關鍵字: | Atopic dermatitis | Comorbidities | Disease burden | Observational study | Treatment patterns | 公開日期: | 1-十二月-2023 | 卷: | 40 | 期: | 12 | 來源出版物: | Advances in Therapy | 摘要: | Introduction: Insights into real-world treatment of atopic dermatitis (AD) are relevant to clinical decision making. The aim of this analysis was to characterize patients who receive dupilumab for AD in a real-world setting. Methods: The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receive dupilumab according to country-specific prescribing information. We report baseline characteristics, comorbidities and treatment patterns for patients enrolled from July 11, 2019 to March 31, 2022. Analyses are descriptive; no formal statistical comparisons were performed. Results: Nine hundred fifty-two adults and adolescents were enrolled in GLOBOSTAD. Patients had a high disease burden before starting dupilumab: (mean [standard deviation]) percent body surface area affected (44.8 [24.42]), Eczema Area and Severity Index total score (24.8 [12.95]), SCORing Atopic Dermatitis total score (60.5 [16.34]), Patient-Oriented Eczema Measure total score (19.7 [6.37]) and Dermatology Life Quality Index total score (13.7 [7.02]). Overall, 741 (77.8%) patients reported ≥ 1 type 2 inflammatory comorbidities, most frequently allergic rhinitis (492 [51.7%]), asthma (323 [33.9%]), food allergy (294 [30.9%]) or another allergy (274 [28.8%]). In the previous 12 months, 310 (32.6%) patients had received systemic non-steroidal immunosuppressants and 169 (17.8%) systemic corticosteroids; 449 (47.2%) had received topical corticosteroids, most commonly potent topical corticosteroids; 141 (14.8%) had received topical calcineurin inhibitors and 32 (3.4%) ultraviolet therapy. Most (713 [74.9%]) patients started dupilumab because of prior treatment failure. Conclusion: Patients enrolled in GLOBOSTAD demonstrated considerable multidimensional burden of disease across AD signs, symptoms and quality of life despite previous use of systemic and non-systemic AD treatments. Clinical Trial Registration: ClinicalTrials.gov identifier NCT03992417. [MediaObject not available: see fulltext.]. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/637042 | ISSN: | 0741238X | DOI: | 10.1007/s12325-023-02644-5 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。